BioCardia, Inc. (BCDA) P/E Ratio History
Historical price-to-earnings valuation from 2011 to 2016
Loading P/E history...
BCDA Valuation Context
How does the current P/E compare to historical and market benchmarks?
P/E Ratio Analysis
As of May 8, 2026, BioCardia, Inc. (BCDA) trades at a price-to-earnings ratio of -0.4x, with a stock price of $1.09 and trailing twelve-month earnings per share of $-1360.34.
The current P/E is 101% below its 5-year average of 38.0x. Over the past five years, BCDA's P/E has ranged from a low of 0.4x to a high of 229.4x, placing the current valuation at the 0th percentile of its historical range.
Compared to the Healthcare sector median P/E of 22.3x, BCDA trades at a 102% discount to its sector peers. The sector includes 241 companies with P/E ratios ranging from 0.0x to 177.5x.
Relative to the broader market, BCDA trades at a notable discount to the S&P 500 median P/E of 25.1x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our BCDA DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
BCDA P/E vs Peers
P/E ratio compared to closely matched public peers
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $74M | 12.1 | - | +103% | |
| $2B | 14.1 | - | -26% | |
| $2B | 109.8 | 2.78Best | +60% | |
| $548M | 11.5Lowest | - | +14% | |
| $7B | 147.0 | - | +287%Best | |
| $84B | 29.2 | - | +55% |
Peers sorted by market capitalization. P/E below peers may indicate undervaluation or lower growth expectations. Consider PEG ratio for growth-adjusted comparison.
BCDA Historical P/E Data (2011–2016)
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Date | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2016 Q3 | Fri Sep 30 2016 00:00:00 GM | $582.96 | $126.23 | 4.6x | -88% |
| FY2016 Q2 | $739.02 | $9.36 | 79.0x | +108% | |
| FY2016 Q1 | $437.58 | $10.77 | 40.6x | +7% | |
| FY2015 Q4 | $388.95 | $9.37 | 41.5x | +9% | |
| FY2015 Q3 | Wed Sep 30 2015 00:00:00 GM | $375.60 | $13.02 | 28.8x | -24% |
| FY2015 Q2 | $447.78 | $13.45 | 33.3x | -12% | |
| FY2015 Q1 | $486.18 | $16.47 | 29.5x | -22% | |
| FY2014 Q4 | Wed Dec 31 2014 00:00:00 GM | $534.60 | $21.94 | 24.4x | -36% |
| FY2014 Q3 | $632.04 | $16.69 | 37.9x | -0% | |
| FY2014 Q2 | Mon Jun 30 2014 00:00:00 GM | $515.37 | $15.47 | 33.3x | -12% |
| FY2014 Q1 | Mon Mar 31 2014 00:00:00 GM | $418.14 | $10.12 | 41.3x | +9% |
| FY2013 Q4 | $408.39 | $1.78 | 229.4x | +504% |
Average P/E for displayed period: 38.0x
See BCDA's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs BCDA Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare BCDA vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonBCDA — Frequently Asked Questions
Quick answers to the most common questions about buying BCDA stock.
Is BCDA stock overvalued or undervalued?
BCDA trades at -0.4x P/E, below its 5-year average of 38.0x. At the N/A percentile of historical range, the stock is priced at a discount to its own history.
How does BCDA's valuation compare to peers?
BioCardia, Inc. P/E of -0.4x compares to sector median of 22.3x. The discount suggests lower growth expectations or higher risk.
What is BCDA's PEG ratio?
BCDA PEG ratio is N/A. Above 2.0 indicates premium valuation relative to growth rate. Historical P/E data spans 2011-2016.